Moderna sues Pfizer for allegedly copying its COVID-19 vaccine technology


Moderna is taking Pfizer and BioNTech to court, accusing the rival drugmakers of patent infringement over their COVID-19 vaccine.
The company said Friday it has filed patent infringement lawsuits against Pfizer and BioNTech in Massachusetts and in Germany, alleging the companies copied its mRNA technology to develop their own coronavirus vaccine and thereby infringed on patents filed by Moderna between 2010 and 2016.
"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," Moderna CEO Stéphane Bancel said. "This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In 2020, Moderna pledged not to enforce patents related to COVID-19 vaccines during the pandemic. By March 2022, though, the company said it "expects those using Moderna-patented technologies will respect the company's intellectual property."
On Friday, Moderna said it has offered to consider a "commercially reasonable license" but that Pfizer and BioNTech have not requested one. The company also said it will "never enforce its patents" for COVID-19 vaccine technology in low-and-middle-income countries.
Moderna is not asking for Pfizer's COVID-19 vaccine to be removed from the marketplace or seeking damages from prior to March 2022. But Moderna Chief Legal Officer Shannon Thyme Klinger said it expects Pfizer and BioNTech "to compensate Moderna" for the "ongoing use of Moderna's patented technologies."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Libya's 'curious' football cup, played in Italy to empty stadiums
Under The Radar 'Curious collaboration' saw Al-Ahli Tripoli crowned league champions in Milan before a handful of spectators
-
What taxes do you pay on a home sale?
The Explainer Some people — though not many — will need to pay capital gains taxes upon selling their home
-
Schools: The return of a dreaded fitness test
Feature Donald Trump is bringing the Presidential Fitness Test back to classrooms nationwide
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages